Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Despite controlling Congress for two years, Republicans have made little progress on drug pricing reform, with only one of six bipartisan Senate bills reaching the floor. At a Senate Judiciary Committee hearing, lawmakers blamed industry pushback and a crowded legislative calendar, while experts called out pharmacy benefit managers (PBMs) and drugmaker tactics like patent thickets as the core drivers of unaffordable drug costs.
Congress admits failure on drug pricing reform — and fingers are pointing everywhere
Despite two years of Republican control in Congress, meaningful drug pricing reform has largely stalled. At a Senate Judiciary Committee hearing this week, Sen. John Kennedy (R-La.) openly admitted embarrassment over the inaction, noting that of six bipartisan bills advanced by the committee last year, only one — targeting biologic patent abuse — has made it to the Senate floor. Industry pushback and a packed legislative calendar are being blamed for the gridlock.
Experts at the hearing zeroed in on two major culprits: drugmaker tactics and pharmacy benefit managers (PBMs). Manufacturers have used strategies like "patent thickets" and "product hopping" to delay cheaper generics and biosimilars, while the three dominant PBMs — CVS Caremark, Express Scripts, and OptumRx — have leveraged their insurer-owned structures to steer patients and squeeze out competition.
Key Takeaways:
Why it matters: With drug affordability remaining a top concern for patients and providers alike, the continued legislative stalemate means millions of Americans are still paying inflated prices — and the system that enables it remains largely intact.